2 *.- Mosaic Laboratories LLC , Lake Forest , CA, U.S.A .
Miguel Aracil - 1 , Lisa M Dauffenbach - 2 , Marta Martínez Diez - 1 , Rana Richeh - 2 , Victoria Moneo - 1 , Juan Fernando Martínez Leal - 1 , Luis Francisco García Fernández - 1 , Christopher A Kerfoot - 2, Carlos M Galmarini - 1 . 
Published online 2013 January 15.
Published February 1 ,Volume 6, Number 2:116-330;2013 :
International Journal of Clinical and Experimental Pathology .
XPG (Xeroderma pigmentosum group G complementing factor) is a protein associated with DNA repair and transcription. Point mutations in ERCC5, the gene coding for XPG, cause the cancer-prone disorder xeroderma pigmentosum (XP) while truncation mutations give rise to individuals with the combined clinical features of XP and Cockayne syndrome. Polymorphisms of ERCC5 or alterations in XPG mRNA expression were also associated to an increase risk of different cancers types and to prognosis of cancer patients. However, the expression of XPG protein in different normal or tumor human tissues is not well known. In the present work, we have validated an immunohistochemistry (IHC) assay for detection of expression levels of XPG protein in FFPE human tissue samples. We have also tested this IHC assay in different normal and tumor human tissues. On a microarray containing 28 normal cores, positive staining was observed in 60% of the samples. The highest staining was detected in adrenal gland, breast, colon, heart, kidney, thyroid and tongue. In tumors, positive staining was observed in 9 of 10 breast cancer samples and in all 5 ovarian cancer and 5 sarcomas samples. Subcellular localization was predominantly nuclear. The use of this validated methodology would help to interpret the role of XPG in tumorogenesis and its use as a possible prognostic or predictive factor....